Literature DB >> 9776263

Nitrogen-13-ammonia and oxygen-15-water estimates of absolute myocardial perfusion in left ventricular ischemic dysfunction.

B L Gerber1, J A Melin, A Bol, D Labar, M Cogneau, C Michel, J L Vanoverschelde.   

Abstract

UNLABELLED: Measurements of resting myocardial blood flow (MBF) in patients with chronic left ventricular ischemic dysfunction by 15O-water with 13N-ammonia and PET have yielded conflicting results. The aim of this study was to perform a head-to-head comparison of both tracers in the same patient population and to answer the question of whether distinctive tracer properties account for differences in estimates of MBF in chronically dysfunctional myocardium by both tracers.
METHODS: A total of 30 patients with chronic dysfunction of the anterior myocardial wall due to significant left anterior descending coronary artery disease underwent PET measurements of absolute MBF in the anterior wall by use of 15O-water and 13N-ammonia before coronary revascularization by either coronary artery bypass graft (n = 24) or percutaneous transluminal coronary angioplasty (n = 6). Improvement of regional contractile function was assessed by two-dimensional echocardiography at a mean of 7.5 +/- 2.1 mo after revascularization. As judged from the changes in anterior myocardial wall motion after revascularization, patients were considered to have either reversibly (n = 16) or persistently (n = 14) dysfunctional myocardium. Estimates of MBF by 15O-water and 13N-ammonia, obtained in every patient before revascularization, were compared among the two patient groups by use of previously validated methods.
RESULTS: With 13N-ammonia, resting regional MBF was significantly higher in reversibly as opposed to persistently dysfunctional segments [84 +/- 8 versus 48 +/- 6 ml (min x 100 g)(-1), mean +/- s.e.m., p < 0.01]. By contrast, no such difference was found when using 15O-water to measure MBF [74 +/- 6 versus 86 +/- 9 ml (min x 100 g)(-1), p = ns]. This was mainly due to the fact that the perfusable tissue fraction (PTF), a fitted parameter of the 15O-water model, was significantly higher in reversibly as opposed to persistently dysfunctional segments (0.63 +/- 0.03 versus 0.50 +/- 0.03, p < 0.05). As a consequence, the 15O-water perfusable tissue index (PTI), which is the ratio of the PTF to the anatomical tissue fraction, was greater in reversibly dysfunctional as opposed to persistently dysfunctional segments (1.07 +/- 0.07 versus 0.79 +/- 0.05, p < 0.01).
CONCLUSION: This study demonstrates significant differences in MBF estimates between 15O-water and 13N-ammonia in chronically dysfunctional ischemic myocardium. Our results indicate that the 15O-water method yields higher absolute MBF values than the 13N-ammonia approach. Our results also support the use of PTI as a marker of myocardial tissue viability.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9776263

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

Review 1.  The perfusable tissue index: a marker of myocardial viability.

Authors:  Paul Knaapen; Ronald Boellaard; Marco J W Götte; Arno P van der Weerdt; Cees A Visser; Adriaan A Lammertsma; Frans C Visser
Journal:  J Nucl Cardiol       Date:  2003 Nov-Dec       Impact factor: 5.952

2.  Impact of scar on water-perfusable tissue index in chronic ischemic heart disease: Evaluation with PET and contrast-enhanced MRI.

Authors:  Paul Knaapen; Olga Bondarenko; Aernout M Beek; Marco J W Götte; Ronald Boellaard; Arno P van der Weerdt; Cees A Visser; Albert C van Rossum; Adriaan A Lammertsma; Frans C Visser
Journal:  Mol Imaging Biol       Date:  2006 Jul-Aug       Impact factor: 3.488

3.  Direct comparison between 2-dimensional and 3-dimensional PET acquisition modes for myocardial blood flow absolute quantification with O-15 water and N-13 ammonia.

Authors:  Véronique Roelants; Anne Bol; Xavier Bernard; Ann Coppens; Jacques Melin; Bernhard Gerber; Jean-Louis Vanoverschelde
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

4.  Blood flow, flow reserve, and glucose utilization in viable and nonviable myocardium in patients with ischemic cardiomyopathy.

Authors:  Xiaoli Zhang; Thomas H Schindler; John O Prior; James Sayre; Magnus Dahlbom; Sung-Cheng Huang; Heinrich R Schelbert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-04       Impact factor: 9.236

Review 5.  Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow?

Authors:  Robert A deKemp; Keiichiro Yoshinaga; Rob S B Beanlands
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

6.  Flow-function relationships in chronic left-ventricular ischemic dysfunction: Impact of the transmurality of infarction.

Authors:  Bernhard L Gerber; Ho Thien Thanh; Véronique Roelants; Agnès Pasquet; David Vancraeynest; Jean-Louis J Vanoverschelde
Journal:  J Nucl Cardiol       Date:  2008-04-16       Impact factor: 5.952

7.  Assessment of myocardial viability in dysfunctional myocardium by resting myocardial blood flow determined with oxygen 15 water PET.

Authors:  Bernd Nowak; Wolfgang M Schaefer; Karl-Christian Koch; Hans-Juergen Kaiser; Stephan Block; Christian Knackstedt; Michael Zimny; Juergen vom Dahl; Udalrich Buell
Journal:  J Nucl Cardiol       Date:  2003 Jan-Feb       Impact factor: 5.952

Review 8.  The role of nuclear imaging in the failing heart: myocardial blood flow, sympathetic innervation, and future applications.

Authors:  Mark J Boogers; Kenji Fukushima; Frank M Bengel; Jeroen J Bax
Journal:  Heart Fail Rev       Date:  2011-07       Impact factor: 4.214

9.  Assessment of myocardial viability using a [15O]-water perfusion PET: Towards a one-stop shop?

Authors:  Christel Hermann Kamani; John O Prior
Journal:  J Nucl Cardiol       Date:  2019-08-21       Impact factor: 5.952

Review 10.  Positron emission tomography for quantitation of myocardial perfusion.

Authors:  Ornella E Rimoldi; Paolo G Camici
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.